StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Guidance uplift and solid free cash flow offset near-term losses, creating potential near-term upside as investors reprice earnings power.
What happened, with direct paths to the underlying reporting
Ashland reported Q4'26 sales of $498 million, up 4% year-over-year, and a net loss of $16 million with adjusted EPS of $1.12. Adjusted EBITDA rose 2% to $121 million, led by Life Sciences and Personal Care, while operating cash flow reached $90 million and ongoing free cash flow was $74 million. The company provided FY2027 guidance of $1.905-$1.975 billion in sales and $405-$435 million in Adjusted EBITDA, signaling a continued earnings trajectory despite near-term profitability pressures.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.